NeuroOne Medical Technologies Files Additional Proxy Materials

TL;DR

NeuroOne Medical filed more proxy docs, check your mail.

AI Summary

NeuroOne Medical Technologies Corp. filed a Definitive Additional Materials document on February 5, 2025, related to its proxy statement. The company, previously known as Original Source Entertainment, Inc., is incorporated in Delaware and headquartered in Eden Prairie, MN. This filing is a supplement to their proxy materials, indicating further information is being provided to shareholders.

Why It Matters

This filing provides additional information to shareholders regarding matters to be voted on at a company meeting, ensuring transparency and informed decision-making.

Risk Assessment

Risk Level: low — This is a routine filing of additional proxy materials, not indicating any immediate financial or operational risk.

Key Players & Entities

• NEUROONE MEDICAL TECHNOLOGIES Corp (company) — Registrant
• Original Source Entertainment, Inc. (company) — Former Company Name
• 20250205 (date) — Filing Date

FAQ

Key Financial Figures

• $100,000 — r all of our stock plans may not exceed $100,000. Options or portions thereof that excee
• $750,000 — non-employee director, will not exceed $750,000 in total value or, in the event such no
• $1,000,000 — to the Board during such calendar year, $1,000,000 in total value. Changes to Capital St

Filing Documents

• ea0229772-defa14a_neuro.htm (DEFA14A) — 267KB
• image_001.jpg (GRAPHIC) — 3KB
• 0001213900-25-010537.txt ( ) — 273KB

From the Filing

ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant  Filed by a Party other than the Registrant   Check the appropriate box: ​Preliminary Proxy Statement ​Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ​Definitive Proxy Statement ​Definitive Additional Materials ​Soliciting Material under §240.14a-12 NeuroOne Medical Technologies Corporation (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): ​No fee required. ​Fee paid previously with preliminary materials ​Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. NeuroOne Medical Technologies Corporation 7599 Anagram Dr. Eden Prairie, MN 55344 SUPPLEMENT TO THE PROXY STATEMENT DATED JANUARY 21, 2025 FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD FEBRUARY 14, 2025 This Supplement (this “Supplement”), dated February 5, 2025, further supplements the definitive proxy statement on Schedule 14A (the “Proxy Statement”) filed by NeuroOne Medical Technologies Corporation, a Delaware corporation, referred to herein as we, us, our or the Company, with the U.S. Securities and Exchange Commission (the “SEC”) on January 21, 2025, in connection with the solicitation by the Company’s Board of Directors (the “Board”), of proxies to be voted at the 2025 Annual Meeting of Stockholders, or any adjournment or postponement thereof (the “Meeting”). THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT, WHICH CONTAINS IMPORTANT ADDITIONAL INFORMATION. Except as to the matters specifically discussed herein, this Supplement does not otherwise modify or update any information or disclosure contained in the Proxy Statement. Capitalized terms used but not otherwise defined in this Supplement shall have the meanings assigned to such terms in the Proxy Statement. EXPLANATORY NOTE The Proxy Statement contains various proposals, including Proposal No. 4, titled “Vote To Approve 2025 Equity Incentive Plan” (“Proposal No. 4”). Proposal No. 4 requests that the Company’s stockholders approve the NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan (the “2025 Plan”). Following the filing of the Proxy Statement, the Company has discussed Proposal No. 4 with certain stockholders and has received feedback regarding certain provisions of the 2025 Plan. In connection with those discussions, the Board believed it in the best interests of the Company to adopt a revised 2025 Plan, contingent upon stockholder approval. On February 4, 2025, the Board adopted the revised 2025 Plan (the “Revised 2025 Plan”). This supplemental filing is intended to provide a summary of the revisions made in the Revised 2025 Plan. As such, the Company is amending and restating certain portions of Proposal No. 4, as detailed below. SUPPLEMENTAL INFORMATION REGARDING PROPOSAL NO. 4 Certain portions of the Proxy Statement are amended and restated as follows (replaced text in strikethrough font and new text in bold and underlined font): PROPOSAL NO. 4 VOTE TO APPROVE 2025 EQUITY INCENTIVE PLAN Our stockholders are being asked to approve the NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan (the “2025 Plan”). Our Board believes that it is in the best interest of us and our stockholders for the Company to be in a position to offer equity awards to executive officers, key employees, outside directors, consultants and advisors in accordance with the terms of the 2025 Plan. We have relied upon and anticipate continuing to rely upon the equity incentive program to a disproportionate degree in lieu of cash compensation to our executive officers. We intend to recruit additional employees and consultants and retain our existing employees and consultants, and the equity available under the Company’s existing incentive plans is not sufficient to support the equity compensation of such consultants and employees. This provides our Board with the discretion to pay a portion of annual bonus payments in the form of equity versus cash. Our Board believes that the structure of these agreements benefits stockholders by providing additional incentive to the executives regarding value creation. The life sciences market is highly competitive, and our results are largely attributable to the talents, expertise, efforts and

View Full Filing

View this DEFA14A filing on SEC EDGAR